Bruno Pougault on the Limitations of DOACs in High-Risk Conditions
Bruno Pougault, Global Marketing Hemostasis Product Manager at HORIBA, shared on LinkedIn:
”DOACs may not be as efficacious or as safe as the current standard of care in conditions such as mechanical heart valves, thrombotic antiphospholipid syndrome, and atrial fibrillation associated with rheumatic heart disease”
Read the full article here.
Article: When Direct Oral Anticoagulants Should Not Be Standard Treatment: JACC State-of-the-Art Review
Authors: Antoine Bejjani, Candrika D. Khairani, Ali Assi, Gregory Piazza, Parham Sadeghipour, Azita H. Talasaz, John Fanikos, Jean M. Connors, Deborah M. Siegal, Geoffrey D. Barnes, Karlyn A. Martin, Dominick J. Angiolillo, Dawn Kleindorfer, Manuel Monreal, David Jimenez, Saskia Middeldorp, Mitchell S. V. Elkind, Christian T. Ruff, Samuel Z. Goldhaber, Harlan M. Krumholz, Roxana Mehran, Mary Cushman, John W. Eikelboom, Gregory Y. H. Lip, Jeffrey I. Weitz, Renato D. Lopes, Behnood Bikdeli
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 27, 2025, 16:00Nathan Connell on WFH AI Summaries from the Global Forum
-
Nov 27, 2025, 15:49Piotr Czempik: Rethinking Coagulation in Acute Liver Dysfunction
-
Nov 27, 2025, 15:35Overwhelmed? A Leader’s Guide from Mark Crowther to Getting Back on Track
-
Nov 27, 2025, 15:10Wolfgang Miesbach’s Top 10 Picks for TTP and Thrombosis from ASH 2025
-
Nov 27, 2025, 14:24ICCBBA’s Executive Director Eoin McGrath Chairs a Dynamic Session on AI, Innovation and Informatics in Transfusion Medicine
-
Nov 27, 2025, 13:26Wolfgang Miesbach’s Top 10 Picks for Bleeding Disorders from ASH 2025
-
Nov 27, 2025, 11:19Priya Prasad Presents a Case of Severe Hypotensive Transfusion Reaction
-
Nov 27, 2025, 04:07Eugene Tang Presents Highlights from UK Stroke Forum 2025
-
Nov 27, 2025, 03:47Michael Makris: I Believe the Time Has Come to Consider Emicizumab Up Front in Persons with Acquired Hemophilia